HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

trimodulin

polyclonal antibody preparation containing IgM (∼23%), IgA (∼21%) and IgG (∼56%)

Also Known As:

BT-588; BT588

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Schüttrumpf, Jörg: 4 articles (12/2021 - 01/2018)
2.	Bohländer, Fabian: 3 articles (12/2021 - 01/2021)
3.	Weißmüller, Sabrina: 3 articles (12/2021 - 01/2021)
4.	Faust, Stefanie: 2 articles (12/2021 - 01/2021)
5.	Gutscher, Marcus: 2 articles (12/2021 - 01/2021)
6.	Riehl, Dennis: 2 articles (12/2021 - 01/2021)
7.	Wartenberg-Demand, Andrea: 2 articles (07/2021 - 01/2018)
8.	Germer, Matthias: 1 article (07/2021)
9.	Heinz, Corina C: 1 article (07/2021)
10.	König, Martin: 1 article (07/2021)

Related Diseases

1.	Pneumonia (Pneumonitis) 01/01/2018 - "Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)." 07/14/2021 - "If applied at a similar concentration range in healthy subjects, trimodulin treatment resulted in C3 and C4 consumption in a concentration-dependent manner, which was extended in patients with severe community-acquired pneumonia. " 01/01/2018 - "The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) containing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add-on therapy for patients with severe community-acquired pneumonia (sCAP). " 11/09/2023 - "The phase II CIGMA trial performed in 160 patients with severe community-acquired pneumonia (sCAP) found treatment with trimodulin (human polyvalent immunoglobulin [Ig]: ~ 23% IgM, ~ 21% IgA, ~ 56% IgG) was associated with a lower mortality in those patients with elevated baseline serum levels of C-reactive protein (CRP) and/or subnormal IgM. "
2.	Inflammation (Inflammations) 11/09/2023 - "In this post hoc analysis, the pharmacodynamic effects of trimodulin treatment (182.6 mg/kg/day for 5 days) were investigated on Ig replenishment, cellular markers of inflammation (absolute neutrophil [ANC] and lymphocyte [ALC] count, neutrophil-to-lymphocyte ratio [NLR]), and soluble markers of inflammation (procalcitonin [PCT] and CRP). " 12/03/2021 - "The IgA component of trimodulin was shown to induce a strong FcαRI-dependent inhibitory immunoreceptor tyrosine-based activation motif (ITAMi) signaling, counteract lipopolysaccharide-induced inflammation and mediate phagocytosis of Staphylococcus aureus. " 01/01/2021 - "We show that COVID-19 associated inflammation could be reduced by addition of human immunoglobulin preparations (IVIG and trimodulin), while trimodulin elicits stronger immune modulation by more powerful ITAMi signaling. "
3.	Infections 07/14/2021 - "Trimodulin may enhance phagocytosis and opsonophagocytosis in patients with severe infections and prevent excessive pathogen lysis and release of harmful anaphylatoxins."
4.	COVID-19 01/01/2021 - "We show that COVID-19 associated inflammation could be reduced by addition of human immunoglobulin preparations (IVIG and trimodulin), while trimodulin elicits stronger immune modulation by more powerful ITAMi signaling. "

Related Drugs and Biologics

1.	Immunoglobulins (Immunoglobulin)
2.	Immunoglobulin A (IgA)
3.	Immunoglobulin G (IgG)
4.	Immunoglobulin M (IgM)
5.	C-Reactive Protein
6.	Intravenous Immunoglobulins (IVIG)
7.	Lipopolysaccharides
8.	Anaphylatoxins
9.	Procalcitonin

Related Therapies and Procedures

1.	Therapeutics